Countdown to 2022 CBIIC:

WU Jinzi

Founder,Chairman and CEO of ASCLETIS PHARMA INC.

Dr. Jinzi J. Wu is Founder, Chairman and CEO of Ascletis which was founded in April 2013. Ascletis is an innovative R&D driven biotech with three commercial products. Led by Dr. Wu, Ascletis (1672.HK) became the first pre-revenue biotech listed on the Hong Kong Stock Exchange in August 2018 and raised US$400M. Under his leadership, Ascletis has developed a fully integrated platform covering the entire value chain from discovery and development to manufacturing and commercialization. Under his leadership, Ascletis is committed to developing and commercializing NASH, cancer lipid metabolism and oral checkpoint inhibitors, viral hepatitis and HIV/AIDS related innovative drugs for unmet medical needs in China and Globally. Dr. Wu has more than 20-year experience covering R&D, GMP manufacturing and commercialization in Big Pharma and biotech. Prior to founding Ascletis, he was Vice President at GSK R&D in USA. He also held various R&D positions from Sr. Scientist to Vice President at Novartis, Immunex/ Amgen and Ambrilia in USA and Canada. Dr Wu obtained his PhD in Cancer Biology from University of Arizona.